CIPLA TAFAMIDIS (Cipla Australia Pty Ltd)
Product name
CIPLA TAFAMIDIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
174 (255 working days)
Active ingredients
tafamidis
Registration type
New generic medicine
Indication
[TRADENAME] is indicated for the treatment of adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM).